Metformin decreases CRC-like organoids viability to the same extent as current chemotherapy without significant effects on WT organoids. by Silvia Cruz-Gil (7037249)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

“…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C⁺ and CD163⁺ macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C⁺, CD163⁺: proinflammatory macrophage cell-surface markers.…”

IMP-1088 decreases infectivity of progeny VACV particles. by Lalita Priyamvada (421536)

Constitutive KIT activation in cells with gain-of function KIT mutations causes increased ROS levels and decreased DJ-1. by Do-Kyun Kim (2176492)

Oleic acid treatment decreases MDA formation, and induces UCP2 and AMPK in septic mice. by Cassiano Felippe Gonçalves-de-Albuquerque (846954)

Serotype distributions over time for reported "non-PCV" serotypes. by Heloisa Ricci Conesa (18291210)

Subjects:

HvPIN1a localisation is influenced by BFA and its expression is decreased by cytokinin. by Gwendolyn K. Kirschner (5142644)

Infection of CD133+ humanized mice resulted in decrease in pathogenicity in HTLV-1-CTCF infected mice. by Ancy Joseph (5634794)

IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)

Models of G48D, M78I, G125C, and A146V RAD52 point mutants. by Abdulaziz B. Hamid (13804692)

Resveratrol decreased tumor latency in <i>Sirt1^Y/+</i> mice. by Katherine V. Clark-Knowles (368164)

Glu58 and Arg87 minimal distance decreases upon activation. by Maxime Louet (150102)

Eltrombopag markedly decreases levels of ROS in MOLM14 cells. by Anna Kalota (7415)

“…B) Graphic presentation of ROS levels measured by flow cytometry in cells treated with E (5 μM) or DPI (25 μM), an inhibitor of NADPH oxidase known to decrease an intracellular level of ROS, or untreated (CTR) cells. …”

Treatment with wt- or S360A-(A)PC decreases infarct area. by Karin C. A. A. Wildhagen (599651)

<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”

M344 decreases orthotopic pancreatic tumor growth when used as a treatment alone or in combination with gemcitabine. by Shelby M. Knoche (13833807)

Compared to vorinostat, M344 decreases pancreatic cancer cell proliferation more effectively for a longer duration. by Shelby M. Knoche (13833807)

Transfer of RSV-infected <i>Kdm5b</i>-deficient DCs leads to a decreased pathogenic pulmonary RSV challenge. by Catherine Ptaschinski (756139)

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”